The role of the serotonergic system in atropine’s anti-myopic effects
The muscarinic cholinergic antagonist atropine is the most widely used pharmacological treatment for the visual disorder myopia (short-sightedness), the leading cause of low-vision worldwide. This study sought to better define the mechanism by which atropine inhibits myopic growth. Although classifi...
Main Authors: | Kate Thomson, Cindy Karouta, Daniel Weber, Nichola Hoffmann, Ian Morgan, Tamsin Kelly, Regan Ashby |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-11-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223013409 |
Similar Items
-
Meta-analysis of the effect and safety of Cyclopentolate and Atropine on ciliary muscle paralysis in myopic children
by: Tong Li, et al.
Published: (2021-05-01) -
Effects of atropine 0.01% on refractive errors in children with myopia
by: Xingxue Zhu, et al.
Published: (2023-08-01) -
The Effect of Long-Term Low-Dose Atropine on Refractive Progression in Myopic Australian School Children
by: William Myles, et al.
Published: (2021-04-01) -
Is 0.01% Atropine an Effective and Safe Treatment for Myopic Children? A Systemic Review and Meta-Analysis
by: Hou-Ren Tsai, et al.
Published: (2021-08-01) -
Treatment of Myopia with Atropine 0.125% Once Every Night Compared with Atropine 0.125% Every Other Night: A Pilot Study
by: Zi-Rong Chen, et al.
Published: (2023-08-01)